Saturday, August 15, 2026

A new study shows insurance denials for brand-name medications surged 67% over the past year. This sharp increase indicates a significant shift in payer strategies for managing high-cost pharmaceuticals, likely driven by the proliferation and expense of GLP-1 weight-loss drugs and other specialty therapies. The data underscores a growing administrative hurdle for practices prescribing these medications. For clinics managing patients on GLP-1s or other branded specialty drugs, this signals an immediate need to bolster pre-service authorization workflows. Audit your recent denials for drugs like semaglutide and tirzepatide, prepare more detailed clinical documentation, and set patient expectations for potential coverage delays. Expect appeal volumes to rise.

Patient Rights Advocate has filed a lawsuit against the American Medical Association, challenging the organization's copyright over the Current Procedural Terminology (CPT) code set. The suit alleges the AMA's control of the codes, which are mandated for use in all HIPAA-standard transactions, constitutes an unlawful monopoly. The outcome could reshape the fundamental infrastructure of medical billing, potentially moving CPT from a proprietary, fee-based system to a public good. While any change would be years away, the legal challenge highlights the foundational friction between a public utility and a private revenue stream that underpins the entire claims process.

The first batch of payer-reported prior authorization metrics, mandated by federal transparency rules, reveals significant variation in denial practices among commercial insurers. Data compiled by KFF shows insurers denied between 12% and 18% of all prior authorization requests in 2025. The data is part of a new federal requirement designed to expose administrative burden, but KFF notes large gaps remain: rates are not broken down by service line, and appeal success data is not yet reported. This establishes a public baseline for denial rates that provider groups can now use in contract negotiations and to challenge systematic denials. Monitor CMS and payer portals for the next data drop, expected in Q1 2027, which will include timeliness metrics and appeal outcomes.

Pharma giant AstraZeneca has joined a coalition of states seeking a preliminary injunction to block an Illinois law that restricts drug manufacturers from limiting 340B drug discounts at community pharmacies. The law, set to take effect January 1, 2027, aims to ensure 340B-covered entities can access discounted drugs through an unlimited number of contract pharmacy partners. AstraZeneca argues the state law is preempted by the federal 340B statute and violates the Commerce Clause. The legal challenge signals continued industry pushback against state-level 340B protections, creating uncertainty for safety-net clinics and hospitals that rely on the program. Track the docket in the Northern District of Illinois for the injunction ruling, expected before year-end.

A growing number of hospital finance leaders are publicly considering exiting Medicare Advantage networks, citing unsustainable administrative burden and reimbursement shortfalls. The shift follows years of increasing prior authorization denials and downward pressure on payment rates from MA plans, which now enroll over half of all Medicare beneficiaries. For independent practices, this trend could mean reduced patient access for MA enrollees and increased pressure to accept traditional Medicare rates if local hospitals drop contracts. The move reflects a broader reevaluation of payer mix as provider margins tighten. This is a structural shift, not an immediate policy change, but it reshapes local referral networks and payer negotiation leverage.